export const tdsTestData = [
  {
    "id": "tds-1",
    "name": "FoundationOne CDx",
    "vendor": "Foundation Medicine",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of FFPE tumor tissue; detects SNVs, indels, CNAs, and select rearrangements in 324 genes; reports MSI, TMB, and HRD signature.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "targetPopulation": "Patients with advanced solid malignant neoplasms requiring genomic profiling to guide treatment decisions",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaStatus": "FDA-approved PMA (P170019) - First FDA-approved broad companion diagnostic for solid tumors",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-f1cdx-p170019s048",
    "fdaApprovalDate": "2017-11-30",
    "fdaApprovalDateCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf",
    "fdaCompanionDxCount": 57,
    "fdaCompanionDxCountNotes": "57 FDA-approved CDx indications in US as of Dec 2025 (100 total CDx indications including Japan). Includes pan-tumor indications for TMB-H, MSI-H, NTRK fusions, RET fusions, and tumor-specific indications across NSCLC, melanoma, breast, colorectal, ovarian, prostate, cholangiocarcinoma, and pediatric brain tumors.",
    "fdaCompanionDxCountCitations": "https://www.businesswire.com/news/home/20251204680697/en/Foundation-Medicine-Achieves-Historic-Milestone-of-100-Approved-and-Active-Companion-Diagnostic-Indications-Solidifying-Leadership-in-Precision-Medicine",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma", "Gastric Cancer", "Cholangiocarcinoma"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers and 'broad molecular profiling' but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-cdx",
    "tat": "8 days",
    "tatNotes": "Typically 8 days or less from receipt of specimen.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "FFPE tissue; minimum 25% tumor content; 10 unstained slides or tissue block",
    "sampleRequirementsNotes": "Foundation Medicine contacts pathology lab for specimen procurement. Can reflex to FoundationOne Liquid CDx if tissue insufficient.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer (CAG-00450R). 87% of patients pay $0 out-of-pocket. 80+ commercial health plans cover Foundation Medicine tests.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance | https://www.foundationmedicine.com/test/foundationone-cdx",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0037U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany). Regulatory: FDA approved (US), MHLW approved (Japan, Dec 2018), CE marked (EU).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25 | https://www.foundationmedicine.com/press-releases/aa55275f-b849-4e31-a770-152c8e7cad8f",
    "clinicalAvailability": "Commercially available in US since 2017; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Foundation Medicine tests cited in >1,000 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1200/JCO.2017.75.3780"]
  },
  {
    "id": "tds-2",
    "name": "FoundationOne Liquid CDx",
    "vendor": "Foundation Medicine",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Hybrid-capture NGS of cfDNA from plasma; analyzes 324 genes; reports short variants in 311 genes, rearrangements in 8 genes, CNAs in 3 genes, plus bTMB and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "genesAnalyzed": 324,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "genesReported": 311,
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "bTMB", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "targetPopulation": "Patients with advanced solid tumors when tissue biopsy is not feasible or as complement to tissue testing",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200006B.pdf",
    "fdaStatus": "FDA-approved PMA (P200006) August 2020",
    "fdaStatusCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaApprovalDate": "2020-08-26",
    "fdaApprovalDateCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic",
    "fdaCompanionDxCount": 10,
    "fdaCompanionDxCountNotes": "Multiple CDx indications in NSCLC (osimertinib, sotorasib, capmatinib), breast cancer (PIK3CA), prostate cancer (BRCA1/2, ATM), cholangiocarcinoma (FGFR2), pan-tumor (NTRK).",
    "fdaCompanionDxCountCitations": "https://www.foundationmedicine.com/press-release/fda-approves-foundationonercdx-and-foundationonerliquid-cdx-companion-diagnostics",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Prostate Cancer", "Cholangiocarcinoma"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-liquid-cdx",
    "tat": "7-10 days",
    "tatNotes": "Results typically available within 7-10 business days.",
    "tatCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL per tube",
    "sampleRequirementsNotes": "7-day sample stability at ambient temperature. Can reflex to tissue testing if liquid negative for CDx mutations.",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/info/detail/order-a-test",
    "reimbursement": "Medicare",
    "reimbursementNote": "National Medicare coverage for advanced cancer. Broad commercial payer coverage.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "cptCodes": "0239U",
    "cptCodesCitations": "https://www.foundationmedicine.com/test/foundationone-cdx",
    "codeType": "PLA",
    "medicareRate": 3500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network. US lab (Cambridge, MA) and EU lab (Penzberg, Germany).",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US since 2020; available in 100+ countries via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-foundationone-liquid-cdx-as-companion-diagnostic"
  },
  {
    "id": "tds-3",
    "name": "FoundationOne Heme",
    "vendor": "Foundation Medicine",
    "sampleCategory": "Tissue/Blood/Bone Marrow",
    "approach": "Tissue + Liquid CGP",
    "method": "Hybrid-capture DNA sequencing of 406 genes plus RNA sequencing of 265 genes for fusion detection; covers hematologic malignancies and sarcomas.",
    "methodCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "genesAnalyzed": 406,
    "genesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "rnaGenesAnalyzed": 265,
    "rnaGenesAnalyzedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "geneListUrl": "https://www.foundationmedicine.com/test/foundationone-heme",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements/Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "cancerTypes": ["Hematologic malignancies", "Sarcomas"],
    "cancerTypesNotes": "Leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and sarcomas.",
    "cancerTypesCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "targetPopulation": "Patients with hematologic malignancies or sarcomas requiring comprehensive genomic profiling",
    "targetPopulationCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "B-Cell Lymphomas", "Myelodysplastic Syndromes", "Soft Tissue Sarcoma"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines for hematologic malignancies and sarcomas. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.foundationmedicine.com/test/foundationone-heme",
    "tat": "10-14 days",
    "tatCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "sampleRequirements": "FFPE tissue, bone marrow aspirate, or peripheral blood depending on disease type",
    "sampleRequirementsCitations": "https://www.foundationmedicine.com/test/foundationone-heme",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage for qualifying patients. Commercial coverage varies.",
    "reimbursementCitations": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
    "listPrice": 3500,
    "listPriceCitations": "https://www.foundationmedicine.com/faq/patient-faqs",
    "availableRegions": ["US", "EU", "UK", "Japan", "Canada", "Australia", "International"],
    "availableRegionsNotes": "Available in 100+ countries via Roche global network.",
    "availableRegionsCitations": "https://www.roche.com/media/releases/med-cor-2021-10-25",
    "clinicalAvailability": "Commercially available in US; available internationally via Roche affiliates",
    "clinicalAvailabilityCitations": "https://www.foundationmedicine.com/test/foundationone-heme"
  },
  {
    "id": "tds-4",
    "name": "Guardant360 CDx",
    "vendor": "Guardant Health",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA; targets 74 genes; reports SNVs, indels, CNAs (6 genes), and fusions (4 genes) with high sensitivity at low allele frequencies.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesAnalyzed": 74,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "genesReported": 55,
    "genesReportedNotes": "74 genes targeted, 55 genes with reportable short variants.",
    "genesReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-cdx",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Fusions"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010B.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "targetPopulation": "Patients with advanced solid tumors; first liquid biopsy with FDA-approved CGP indication for all solid tumors",
    "targetPopulationCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "fdaStatus": "FDA-approved PMA (P200010) August 2020 - First FDA-approved liquid biopsy NGS CDx",
    "fdaStatusCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008 | https://www.targetedonc.com/view/fda-approves-guardant360-cdx-for-tumor-mutation-profiling-of-all-solid-cancers",
    "fdaApprovalDate": "2020-08-07",
    "fdaApprovalDateCitations": "https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s008",
    "fdaCompanionDxCount": 6,
    "fdaCompanionDxCountNotes": "6 CDx indications: NSCLC (osimertinib/EGFR, amivantamab/EGFR exon 20, trastuzumab deruxtecan/ERBB2, sotorasib/KRAS G12C); Breast cancer (elacestrant/ESR1, imlunestrant/ESR1).",
    "fdaCompanionDxCountCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx | https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer"],
    "nccnGuidelinesNotes": "Covers all genes recommended by NCCN for NSCLC and relevant biomarkers for breast cancer treatment. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.guardanthealth.com/",
    "tat": "5-7 days",
    "tatNotes": "Actionable results typically within 7 days; as fast as 5 days.",
    "tatCitations": "https://www.onclive.com/view/fda-clears-guardant360-cdx-as-companion-diagnostic-for-imlunestrant-in-esr1-mutated-breast-cancer",
    "sampleRequirements": "2 tubes of whole blood in Streck cfDNA BCT tubes; minimum 5 mL",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S008C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Broadly covered by Medicare and commercial insurers representing >300 million lives.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer/default.aspx",
    "cptCodes": "0242U",
    "codeType": "PLA",
    "medicareRate": 5000,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available in US since 2020",
    "clinicalAvailabilityCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "numPublications": 150,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": "Guardant360 cited in >150 peer-reviewed publications (vendor estimate).",
    "numPublicationsCitations": "https://www.cancernetwork.com/view/fda-approves-guardant360-cdx-for-comprehensive-genomic-profiling-in-all-solid-cancers",
    "publicationsExampleCitations": ["https://pubmed.ncbi.nlm.nih.gov/33619370/", "https://pubmed.ncbi.nlm.nih.gov/37256839/"]
  },
  {
    "id": "tds-17",
    "name": "Guardant360 Liquid",
    "vendor": "Guardant Health",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Digital sequencing of cfDNA on Guardant Infinity platform; targets 744 genes; reports SNVs, indels, CNAs, CNLs, fusions/rearrangements, MSI, TMB, tumor fraction, and promoter methylation (epigenomic features). CHIP filtering via proprietary algorithm. Virus detection (EBV, HPV).",
    "methodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesAnalyzed": 744,
    "genesAnalyzedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "genesReported": 744,
    "genesReportedNotes": "Full 744-gene panel reported. 10x more genes than previous Guardant360 version and 10x higher sensitivity for tumor fraction quantification.",
    "genesReportedCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "geneListUrl": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "CNLs", "Fusions/Rearrangements", "MSI", "TMB", "Tumor Fraction", "Promoter Methylation"],
    "biomarkersReportedNotes": "First and only liquid biopsy to deliver genomic and epigenomic insights (promoter methylation) from a single input. CHIP variants flagged via proprietary algorithm.",
    "biomarkersReportedCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "targetPopulation": "Patients with advanced solid tumors; comprehensive genomic and epigenomic profiling for treatment selection",
    "targetPopulationCitations": "https://guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/",
    "fdaStatus": "CLIA LDT; not FDA-cleared/approved",
    "fdaStatusNotes": "Developed as a Laboratory Developed Test (LDT) by Guardant Health Clinical Laboratory (CLIA-certified). Distinct from Guardant360 CDx which is FDA-approved but covers only 74 genes.",
    "fdaStatusCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "fdaCompanionDxCount": 0,
    "fdaCompanionDxCountNotes": "LDT version - no FDA companion diagnostic claims. For FDA-approved CDx, see Guardant360 CDx.",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "nccnGuidelinesNotes": "Covers all guideline-recommended genomic biomarkers across advanced solid tumors plus emerging biomarkers. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "tat": "7 days",
    "tatNotes": "Median 7 days from sample receipt to results.",
    "tatCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "sampleRequirements": "Two 10 mL tubes of whole blood; ship same or next day at room temperature (do not freeze/refrigerate)",
    "sampleRequirementsCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "lod": "SNVs: 0.20% VAF; Indels: 0.26%; CNAs: 2.46 copies; Fusions: 0.05%; MSI: 0.05%; Tumor Fraction: 1.6%",
    "lodNotes": "LoD defined as allele fraction/copy number at 95% probability of detection for oncogenic variants. TMB evaluable at ≥0.3% sample allele fraction.",
    "lodCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "specificity": "≥99.9% for SNVs, Indels, CNAs, CNLs, Fusions, MSI, Promoter Methylation",
    "specificityCitations": "https://www.guardantcomplete.com/assets/pdf/Guardant360-Liquid-Specification-Sheet.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "Covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors.",
    "reimbursementCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx",
    "availableRegions": ["US"],
    "availableRegionsNotes": "US availability via Guardant Health. International availability via regional spec sheets (AMEA region).",
    "availableRegionsCitations": "https://www.guardantcomplete.com/hcp/solutions/guardant360-liquid/",
    "clinicalAvailability": "Commercially available in US; 2024 major upgrade launched",
    "clinicalAvailabilityCitations": "https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Introduces-Major-Smart-Liquid-Biopsy-Upgrade-to-Market-Leading-Guardant360-Test-Further-Extending-Its-Best-in-Class-Performance/default.aspx"
  },
  {
    "id": "tds-5",
    "name": "Tempus xT CDx",
    "vendor": "Tempus AI",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Tumor-normal matched NGS of FFPE tissue and matched normal blood/saliva; detects SNVs, MNVs, indels in 648 genes plus MSI status; tumor-normal matching improves somatic variant accuracy.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "genesAnalyzed": 648,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/ | https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "biomarkersReported": ["SNVs", "MNVs", "Indels", "CNVs", "Rearrangements", "TMB", "MSI"],
    "biomarkersReportedNotes": "HRD and HLA genotyping available as add-ons via professional services report.",
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "targetPopulation": "Patients with previously diagnosed solid malignant neoplasms",
    "targetPopulationCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "fdaStatus": "FDA-approved IVD (P210011) - National launch January 2025",
    "fdaStatusCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test | https://investors.tempus.com/news-releases/news-release-details/tempus-announces-national-launch-fda-approved-xt-cdx-test",
    "fdaApprovalDate": "2024-06-01",
    "fdaApprovalDateCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxCountNotes": "CDx claims for colorectal cancer (KRAS, NRAS, BRAF); positioned as one of the largest FDA-approved gene panels.",
    "fdaCompanionDxCountCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Colorectal Cancer", "Breast Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "tat": "14 days",
    "tatNotes": "Results typically within 14 days.",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/",
    "sampleRequirements": "FFPE tissue plus matched normal (blood or saliva)",
    "sampleRequirementsNotes": "Tumor-normal matched approach differentiates somatic from germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210011C.pdf",
    "reimbursement": "Medicare",
    "reimbursementNote": "CMS Advanced Diagnostic Laboratory Test (ADLT) designation; Medicare rate $4,500.",
    "reimbursementCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "listPrice": 4500,
    "listPriceCitations": "https://www.360dx.com/business-news/tempus-nabs-cms-advanced-diagnostic-laboratory-test-status-tumor-mutation-profiling",
    "cptCodes": "0473U",
    "cptCodesCitations": "https://www.discoveriesinhealthpolicy.com/2024/09/cms-releases-preliminary-crosswalk-for.html",
    "codeType": "PLA",
    "medicareRate": 4500,
    "medicareStatus": "Priced",
    "medicareEffective": "2025-Q4",
    "adltStatus": true,
    "clinicalAvailability": "Commercially available nationwide since January 2025",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/tempus-announces-the-national-launch-of-fda-approved-xt-cdx-test",
    "complementaryTests": "Can add xR RNA sequencing, xF/xF+ liquid biopsy, HER2 IHC, PD-L1 IHC, HRD, Immune Profile Score",
    "complementaryTestsCitations": "https://www.tempus.com/oncology/genomic-profiling/xt-xr/"
  },
  {
    "id": "tds-6",
    "name": "Tempus xF",
    "vendor": "Tempus AI",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "ctDNA NGS panel targeting 105 genes; detects SNVs, indels, CNGs (6 genes), CNLs (BRCA1/2), and rearrangements (6 genes) plus MSI-H.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/ | https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "analyticalValidation": "Validated performance metrics from Finkle et al. 2021 analytical validation study.",
    "analyticalValidationCitations": "https://www.tempus.com/wp-content/uploads/2021/09/xF-Validation-Summary.pdf",
    "genesAnalyzed": 105,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "Select CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients with advanced solid tumors; not intended for hematologic malignancies, early-stage cancers, or primary CNS malignancies",
    "targetPopulationCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "nccnGuidelinesNotes": "Covers key biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xf/",
    "tat": "5-7 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Commercial and Medicare coverage varies by indication.",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sensitivity": ">99% for SNVs/CNGs at ≥0.5% VAF; >98% for indels; >97% for rearrangements",
    "sensitivityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/",
    "specificity": ">99.9% for SNVs, indels, rearrangements; >96% for CNGs",
    "specificityCitations": "https://www.ncbi.nlm.nih.gov/gtr/tests/569040/"
  },
  {
    "id": "tds-7",
    "name": "Tempus xF+",
    "vendor": "Tempus AI",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Expanded ctDNA NGS panel targeting 523 genes; detects SNVs, indels, CNGs, and rearrangements; includes clonal hematopoiesis (CH) variant identification.",
    "methodCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "analyticalValidation": "Validated per Boulos et al. 2025 analytical validation study.",
    "analyticalValidationCitations": "https://pubmed.ncbi.nlm.nih.gov/39820598/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "geneListUrl": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Rearrangements", "CH variants"],
    "biomarkersReportedCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "targetPopulation": "Patients requiring expanded liquid biopsy coverage",
    "targetPopulationCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "nccnGuidelinesNotes": "Expanded 523-gene panel covers all biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.tempus.com/oncology/genomic-profiling/xf/",
    "tat": "7-10 days",
    "tatCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "sampleRequirements": "Blood in Streck cfDNA BCT tubes",
    "sampleRequirementsCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "reimbursement": "Coverage Varies",
    "reimbursementCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.tempus.com/oncology/genomic-profiling/xf/"
  },
  {
    "id": "tds-8",
    "name": "MSK-IMPACT",
    "vendor": "Memorial Sloan Kettering",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS of matched tumor/normal FFPE tissue; targets 468 cancer-associated genes covering ~1.5Mb of the genome; detects SNVs, indels, CNAs, select rearrangements, and MSI.",
    "methodCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://www.mskcc.org/msk-impact",
    "genesAnalyzed": 468,
    "genesAnalyzedNotes": "468 genes in original FDA-authorized configuration (2017); panel has since expanded to ~505 genes per current MSK documentation.",
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf | https://ascopost.com/News/58263 | https://www.mskcc.org/msk-impact",
    "geneListUrl": "https://www.mskcc.org/msk-impact",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Rearrangements", "MSI"],
    "biomarkersReportedCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.mskcc.org/msk-impact",
    "targetPopulation": "Patients with advanced cancer treated at Memorial Sloan Kettering Cancer Center",
    "targetPopulationCitations": "https://www.mskcc.org/msk-impact",
    "fdaStatus": "FDA authorized (de novo, DEN170058) November 2017 - First tumor-profiling LDT to receive FDA authorization",
    "fdaStatusCitations": "https://ascopost.com/News/58263 | https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors",
    "fdaAuthorizationDate": "2017-11-15",
    "fdaAuthorizationDateCitations": "https://ascopost.com/News/58263",
    "fdaStatusNotes": "Not FDA-approved as CDx; authorized for tumor mutation profiling. Also approved by NYSDOH.",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Melanoma", "Ovarian Cancer", "Gastric Cancer"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines for major solid tumors. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.mskcc.org/msk-impact",
    "tat": "2-3 weeks",
    "tatCitations": "https://www.mskcc.org/msk-impact",
    "sampleRequirements": "FFPE tumor tissue plus matched normal sample",
    "sampleRequirementsNotes": "Tumor-normal matching allows accurate distinction of somatic vs germline variants.",
    "sampleRequirementsCitations": "https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage depends on payer; available primarily to MSK patients.",
    "reimbursementCitations": "https://www.mskcc.org/msk-impact",
    "clinicalAvailability": "Available only at Memorial Sloan Kettering Cancer Center",
    "clinicalAvailabilityNotes": "Single-site assay; >20,000 patients sequenced since 2014. Results accessible via cBioPortal and annotated using OncoKB.",
    "clinicalAvailabilityCitations": "https://www.mskcc.org/msk-impact | https://www.mskcc.org/news-releases/msk-impact-first-tumor-profiling-multiplex-panel-authorized-fda-setting-new-pathway-market-future-oncopanels",
    "numPublications": 1000,
    "numPublicationsPlus": true,
    "numPublicationsSource": "vendor-estimate",
    "numPublicationsNotes": ">1,000 peer-reviewed publications featuring MSK-IMPACT data as of end of 2024 (vendor estimate).",
    "numPublicationsCitations": "https://www.mskcc.org/msk-impact",
    "publicationsExampleCitations": ["https://doi.org/10.1038/nm.4333", "https://doi.org/10.1056/NEJMoa1610624"],
    "keyFindings": "37% of profiled patients have at least one actionable mutation; 11% enrolled in matched clinical trials.",
    "keyFindingsCitations": "https://www.mskcc.org/news/fda-authorizes-msk-impact-test-analyzing-patient-tumors | https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer"
  },
  {
    "id": "tds-9",
    "name": "MI Cancer Seek",
    "vendor": "Caris Life Sciences",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Combined whole exome sequencing (WES) and whole transcriptome sequencing (WTS) from single FFPE tissue extraction; detects SNVs, indels in 228 genes, MSI, TMB, and ERBB2 amplification.",
    "methodCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC12581394/",
    "genesAnalyzed": 228,
    "genesAnalyzedNotes": "228 genes with reportable SNVs/indels in CDx subset; WES/WTS technically interrogates ~20,000 genes for research findings and signatures. This prevents confusion between '228 genes' and 'whole-exome' claims.",
    "genesAnalyzedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "geneListUrl": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "biomarkersReported": ["SNVs", "Indels", "MSI", "TMB", "ERBB2 CNA"],
    "biomarkersReportedCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "targetPopulation": "Adults and pediatric patients (ages 1-22) with previously diagnosed solid malignant neoplasms",
    "targetPopulationNotes": "First and only FDA-approved CGP with CDx indications for both adult and pediatric patients.",
    "targetPopulationCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaStatus": "FDA-approved IVD (P240010) November 2024 - First WES+WTS combined assay with CDx indications",
    "fdaStatusCitations": "https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/ | https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaApprovalDate": "2024-11-06",
    "fdaApprovalDateCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "fdaCompanionDxCount": 8,
    "fdaCompanionDxCountNotes": "8 CDx claims: 1 pan-cancer indication plus 5 tumor-specific indications (breast, colorectal, melanoma, NSCLC, endometrial). Includes PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H.",
    "fdaCompanionDxCountCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Endometrial Cancer"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines including PIK3CA, KRAS, NRAS, BRAF, MSI-H/TMB-H. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "tat": "14 days",
    "tatNotes": "Results within 14 days.",
    "tatCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/cdx-indications/",
    "sampleRequirements": "FFPE tissue; minimum 20% tumor content",
    "sampleRequirementsNotes": "Simultaneous DNA and RNA extraction from single sample minimizes tissue requirements compared to separate assays.",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/ | https://www.mlo-online.com/diagnostics/assays/news/55241478/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage expanding; contact Caris for current payer coverage.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/physician-tests/mi-cancer-seek/",
    "clinicalAvailability": "Commercially available in US since November 2024",
    "clinicalAvailabilityCitations": "https://www.biospace.com/press-releases/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek-as-a-companion-diagnostic-cdx-test",
    "analyticalValidation": "97-100% positive and negative percent agreement compared to other FDA-approved assays",
    "analyticalValidationCitations": "https://www.prnewswire.com/news-releases/caris-life-sciences-demonstrates-scientific-rigor-with-clinical-validation-of-fda-approved-mi-cancer-seek-302530610.html"
  },
  {
    "id": "tds-11",
    "name": "OncoExTra",
    "vendor": "Exact Sciences",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP (WES + WTS)",
    "method": "Whole exome sequencing (WES) of ~20,000 genes combined with whole transcriptome sequencing (WTS) from FFPE tissue; reports SNVs, indels, CNAs, fusions, MSI, TMB, and HRD status.",
    "methodCitations": "https://www.exactsciences.com/test/oncoextra | https://www.oncotarget.com/article/28285/text/",
    "genesAnalyzed": 20000,
    "genesAnalyzedNotes": "WES/WTS comprehensively interrogates ~20,000 genes; reportable subset varies by biomarker type.",
    "genesAnalyzedCitations": "https://www.exactsciences.com/test/oncoextra",
    "geneListUrl": "https://www.exactsciences.com/test/oncoextra",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "HRD"],
    "biomarkersReportedCitations": "https://www.exactsciences.com/test/oncoextra",
    "cancerTypes": ["Advanced solid tumors"],
    "cancerTypesCitations": "https://www.exactsciences.com/test/oncoextra",
    "targetPopulation": "Patients with advanced solid tumors requiring comprehensive genomic and transcriptomic profiling",
    "targetPopulationCitations": "https://www.exactsciences.com/test/oncoextra",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.exactsciences.com/test/oncoextra",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer", "Melanoma"],
    "nccnGuidelinesNotes": "WES/WTS approach covers all biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.exactsciences.com/test/oncoextra",
    "tat": "10-14 days",
    "tatCitations": "https://www.exactsciences.com/test/oncoextra",
    "sampleRequirements": "FFPE tissue; 10 unstained slides or tissue block",
    "sampleRequirementsCitations": "https://www.exactsciences.com/test/oncoextra",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage; commercial coverage varies by payer.",
    "reimbursementCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.exactsciences.com/test/oncoextra",
    "clinicalUtility": "Studies demonstrate increased matched therapy rates compared to single-gene testing.",
    "clinicalUtilityCitations": "https://www.oncotarget.com/article/28285/text/ | https://pubmed.ncbi.nlm.nih.gov/37256839/"
  },
  {
    "id": "tds-12",
    "name": "OmniSeq INSIGHT",
    "vendor": "Labcorp Oncology (OmniSeq)",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP + Immune Profiling",
    "method": "NGS panel covering full coding regions of 523 genes plus immune profiling including PD-L1 expression and immune signatures; detects SNVs, indels, CNAs, fusions, TMB, and MSI.",
    "methodCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight | https://pmc.ncbi.nlm.nih.gov/articles/PMC8796288/",
    "genesAnalyzed": 523,
    "genesAnalyzedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "geneListUrl": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "PD-L1", "Immune Signatures"],
    "biomarkersReportedNotes": "Combined genomic and immune profiling in single test.",
    "biomarkersReportedCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic and immune profiling",
    "targetPopulationCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines plus immune profiling. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "tat": "10-14 days",
    "tatCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare and commercial coverage; widely available via Labcorp network.",
    "reimbursementCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight",
    "clinicalAvailability": "Commercially available in US via Labcorp network",
    "clinicalAvailabilityCitations": "https://oncology.labcorp.com/providers/order-a-test/omniseq-insight"
  },
  {
    "id": "tds-13",
    "name": "StrataNGS",
    "vendor": "Strata Oncology",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Multiplex PCR/semiconductor sequencing panel targeting 429 genes; detects SNVs, indels, CNAs, select fusions, TMB, and MSI.",
    "methodCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/",
    "genesAnalyzed": 429,
    "genesAnalyzedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "geneListUrl": "https://www.strataoncology.com/stratangs",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Select Fusions", "TMB", "MSI"],
    "biomarkersReportedCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.strataoncology.com/stratangs",
    "targetPopulation": "Patients with advanced solid tumors requiring genomic profiling",
    "targetPopulationCitations": "https://www.strataoncology.com/stratangs",
    "fdaStatus": "CLIA LDT - not FDA approved",
    "fdaStatusCitations": "https://www.strataoncology.com/stratangs",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer", "Ovarian Cancer"],
    "nccnGuidelinesNotes": "Covers biomarkers recommended by NCCN guidelines. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.strataoncology.com/stratangs",
    "tat": "7-10 days",
    "tatCitations": "https://www.strataoncology.com/stratangs",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.strataoncology.com/stratangs",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare-covered CGP; specific footprint in health-system networks.",
    "reimbursementCitations": "https://www.strataoncology.com/stratangs",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.strataoncology.com/stratangs",
    "clinicalUtility": "Published data on access and outcomes in real-world settings.",
    "clinicalUtilityCitations": "https://ascopubs.org/doi/10.1200/PO.21.00088 | https://pubmed.ncbi.nlm.nih.gov/34723565/"
  },
  {
    "id": "tds-14",
    "name": "MI Profile",
    "vendor": "Caris Life Sciences",
    "sampleCategory": "Tissue",
    "approach": "Tissue Multi-omic Profiling",
    "method": "Comprehensive multi-omic profiling combining WES, WTS, and protein analysis (IHC/FISH) from FFPE tissue; reports DNA variants, RNA fusions, and protein expression.",
    "methodCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/molecular-intelligence-platform/",
    "genesAnalyzed": 22000,
    "genesAnalyzedNotes": "WES/WTS interrogates ~22,000 genes; protein analysis adds expression-level biomarkers.",
    "genesAnalyzedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "geneListUrl": "https://www.carislifesciences.com/physicians/profiling/",
    "biomarkersReported": ["SNVs", "Indels", "CNAs", "Fusions", "TMB", "MSI", "Protein Expression"],
    "biomarkersReportedNotes": "Multi-omic approach combines genomic, transcriptomic, and proteomic data.",
    "biomarkersReportedCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "targetPopulation": "Patients requiring comprehensive multi-omic tumor profiling",
    "targetPopulationCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "fdaStatus": "CLIA LDT - MI Cancer Seek component FDA approved; full MI Profile is LDT",
    "fdaStatusNotes": "MI Cancer Seek (WES+WTS component) received FDA approval Nov 2024; MI Profile as comprehensive service remains CLIA LDT.",
    "fdaStatusCitations": "https://www.carislifesciences.com/physicians/profiling/ | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Gastric Cancer"],
    "nccnGuidelinesNotes": "Multi-omic approach covers biomarkers recommended by NCCN guidelines at DNA, RNA, and protein levels. NCCN guidelines recommend testing specific genes/biomarkers but do not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1 | https://www.carislifesciences.com/physicians/profiling/",
    "tat": "10-14 days",
    "tatCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "sampleRequirements": "FFPE tissue",
    "sampleRequirementsCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer and specific tests ordered.",
    "reimbursementCitations": "https://www.carislifesciences.com/physicians/profiling/",
    "clinicalAvailability": "Commercially available in US",
    "clinicalAvailabilityCitations": "https://www.carislifesciences.com/physicians/profiling/"
  },
  {
    "id": "tds-15",
    "name": "NEO PanTracer Tissue",
    "previousName": "Neo Comprehensive",
    "vendor": "NeoGenomics",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Comprehensive genomic profiling using DNA and RNA NGS; detects SNVs, indels, CNVs, fusions, splice variants, MSI, and TMB across 517 genes from FFPE tissue samples.",
    "methodCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/235/neogenomics-expands-ngs-portfolio-with-launch-of-neo | https://www.neogenomics.com/test-menu",
    "genesAnalyzed": 517,
    "genesAnalyzedNotes": "517 genes analyzed via both DNA and RNA NGS methods.",
    "genesAnalyzedCitations": "NeoGenomics press release March 2023; NeoGenomics test menu.",
    "geneListUrl": "https://www.neogenomics.com/test-menu",
    "biomarkersReported": ["SNVs", "Indels", "CNVs", "Fusions", "Splice variants", "TMB", "MSI"],
    "biomarkersReportedNotes": "Comprehensive biomarker detection including both DNA alterations and RNA fusions/splice variants.",
    "biomarkersReportedCitations": "NeoGenomics press release March 2023.",
    "cancerTypes": ["All solid tumors"],
    "cancerTypesCitations": "https://www.neogenomics.com/test-menu",
    "targetPopulation": "Patients with solid tumors requiring comprehensive genomic profiling for diagnosis, therapy selection, prognosis, and clinical trial eligibility",
    "targetPopulationCitations": "NeoGenomics test menu; press releases.",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified and CAP-accredited laboratory-developed test. New York State approved (Jan 2024).",
    "fdaStatusCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Prostate Cancer", "Ovarian Cancer"],
    "nccnGuidelinesNotes": "Pan-cancer CGP aligns with NCCN guidelines for solid tumor biomarker testing. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "tat": "7-10 days",
    "tatNotes": "Improved turnaround time compared to previous NeoGenomics panels. Streamlined workflow.",
    "tatCitations": "NeoGenomics press release March 2023.",
    "sampleRequirements": "FFPE tissue (decreased specimen requirements vs previous panels)",
    "sampleRequirementsCitations": "NeoGenomics press release March 2023.",
    "reimbursement": "Coverage Varies",
    "reimbursementNote": "Coverage varies by payer. Medicare coverage for CGP in advanced solid tumors. Commercial coverage varies.",
    "reimbursementCitations": "NeoGenomics website.",
    "clinicalAvailability": "Commercially available in US (including NY State)",
    "clinicalAvailabilityCitations": "https://ir.neogenomics.com/news-events/press-releases/detail/276/neogenomics-receives-new-york-state-approval-for-neo",
    "numPublications": null,
    "numPublicationsNotes": "Platform launched March 2023; publication record building.",
    "regulatoryStatusNotes": "CAP-accredited and CLIA-certified laboratories in Fort Myers and Tampa, FL; Aliso Viejo and San Diego, CA; Research Triangle Park, NC; and Houston, TX. New York State approved January 2024."
  },
  {
    "id": "tds-16",
    "name": "Northstar Select",
    "vendor": "BillionToOne",
    "sampleCategory": "Blood/Plasma",
    "approach": "Liquid CGP",
    "method": "Single-molecule NGS (smNGS) with QCT™ (Quantitative Counting Templates) for cfDNA analysis. 84-gene panel optimized for sensitivity over breadth. Detects SNVs, indels, CNAs (amplifications and losses), fusions, and MSI-H. Unique ability to differentiate focal copy number changes from aneuploidies using insights from >1 million cfDNA tests for fetal aneuploidy.",
    "methodCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action | Bower X et al. J Liq Biopsy 2025;9:1003222",
    "genesAnalyzed": 84,
    "genesAnalyzedNotes": "84-gene panel: 82 genes for SNV/indels, 19 genes for CNA amplification, 5 genes for CNA loss, 9 genes for fusions. Panel designed for actionability over breadth.",
    "genesAnalyzedCitations": "https://www.northstaronc.com/",
    "geneListUrl": "https://cdn.prod.website-files.com/676903c0e34284138d6e0066/68e3c65e20bf5b7173202a4f_NS-SEL-FL-001-2509%20-%20Spec%20Sheet%20-%20DIGITAL.pdf",
    "biomarkersReported": ["SNVs", "Indels", "CNAs (amplification)", "CNAs (loss)", "Fusions", "MSI-H"],
    "biomarkersReportedNotes": "Reports guideline-recommended alterations with focus on actionability. Unique capability to detect CNA losses and differentiate focal driver amplifications from broad chromosomal aneuploidies.",
    "biomarkersReportedCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "cancerTypes": ["Advanced solid tumors (17+ types)", "CNS cancers", "Low-shedding tumors"],
    "cancerTypesCitations": "https://www.prnewswire.com/news-releases/billiontoones-northstar-select-demonstrates-superior-sensitivity-in-prospective-head-to-head-validation-study-publication-302539192.html",
    "targetPopulation": "Patients with stage III or IV solid tumors requiring comprehensive genomic profiling, particularly when tissue is not feasible or for low-shedding tumors",
    "targetPopulationCitations": "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "sensitivity": null,
    "sensitivityNotes": "In prospective head-to-head validation (n=182), detected 51% more pathogenic SNV/Indels and 109% more CNVs than comparator assays. 87% detection rate in CNS cancers vs 27-55% reported for other liquid biopsies. 91% of additional clinically actionable variants found below 0.5% VAF.",
    "sensitivityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072",
    "specificity": 99.9,
    "specificityNotes": ">99.9% analytical specificity across all variant classes. 98% concordance with ddPCR orthogonal validation. CHIP rate equivalent to comparators (19.0% vs 17.2%), confirming additional detections are true positives.",
    "specificityCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "lod": "0.15% VAF",
    "lodNotes": "LOD95 of 0.15% VAF for SNVs - among the lowest in commercially available liquid biopsy CGP. 2-5x lower LOD than comparator assays.",
    "lodCitations": "https://www.northstaronc.com/ | Bower X et al. J Liq Biopsy 2025",
    "fdaStatus": "CLIA LDT - NOT FDA approved",
    "fdaStatusNotes": "CLIA-certified laboratory-developed test. CAP-accredited.",
    "fdaStatusCitations": "https://www.northstaronc.com/",
    "nccnRecommended": true,
    "nccnAlignmentType": "biomarker-coverage",
    "nccnGuidelinesAligned": ["NSCLC", "Breast Cancer", "Colorectal Cancer", "Prostate Cancer"],
    "nccnGuidelinesNotes": "84-gene panel covers guideline-recommended biomarkers. NCCN recommends testing specific genes/biomarkers but does not endorse specific commercial assays by name.",
    "nccnGuidelinesCitations": "https://www.nccn.org/guidelines/category_1",
    "tat": "5-8 days",
    "tatNotes": "Typical turnaround time 5-8 days from specimen receipt.",
    "tatCitations": "https://www.northstaronc.com/insights/introducing-northstar-select-a-liquid-biopsy-built-for-clinical-action",
    "sampleRequirements": "Blood draw (plasma cfDNA)",
    "sampleRequirementsCitations": "https://www.northstaronc.com/",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage via MolDx (Palmetto GBA LCD L38043) effective February 14, 2025 for eligible beneficiaries with advanced solid tumors.",
    "reimbursementCitations": "https://www.billiontoone.com/news-media/billiontoone-announces-medicare-coverage-for-northstar-select",
    "clinicalAvailability": "Commercially available in US since January 2023",
    "clinicalAvailabilityCitations": "https://www.delveinsight.com/asco-conference/article/billiontoone-northstar-select",
    "numPublications": 2,
    "numPublicationsNotes": "Peer-reviewed validation study published September 2025 in Journal of Liquid Biopsy. ASCO 2024 abstract.",
    "numPublicationsCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222 | JCO 2024;42:16_suppl,3072",
    "publicationsExampleCitations": ["https://www.journalofliquidbiopsy.com/article/S2950-1954(25)00038-4/fulltext", "https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3072"],
    "technologyDifferentiator": "Only liquid biopsy with prospective head-to-head peer-reviewed publication showing superior sensitivity vs multiple commercially available comparators. smNGS with QCT technology enables single-molecule precision. Unique ability to detect CNA losses and differentiate focal amplifications from aneuploidies.",
    "independentValidation": "Prospective head-to-head validation against 6 commercially available assays from 4 CLIA/CAP labs (n=182 patients, 17+ tumor types, 6 community clinics + 1 hospital). Orthogonal ddPCR validation showed 98% concordance.",
    "independentValidationCitations": "Bower X et al. J Liq Biopsy 2025;9:1003222",
    "vendorDataSource": "Rob Manor (BillionToOne) submission Dec 2025"
  },
  {
    "id": "tds-18",
    "name": "IsoPSA",
    "vendor": "Cleveland Diagnostics",
    "sampleCategory": "Blood/Serum",
    "approach": "Protein Structure Analysis",
    "method": "IsoClear platform analyzes structural differences in PSA protein isoforms to distinguish cancer-derived PSA from benign elevations. Measures prostate cancer-specific structural variants of the PSA protein rather than total PSA concentration. Runs on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad deployment from large centers to community practices.",
    "methodCitations": "Klein EA et al. Eur Urol 2017 | Stovsky M et al. J Urol 2019",
    "cancerTypes": ["Prostate cancer (high-grade)"],
    "cancerTypesNotes": "Specifically designed to detect high-grade (clinically significant) prostate cancer, helping avoid unnecessary biopsies for low-grade or benign conditions.",
    "targetPopulation": "Men ≥50 years of age with elevated PSA levels who are candidates for prostate biopsy decision-making",
    "targetPopulationCitations": "FDA PMA approval December 2025",
    "indicationsNotes": "Aid in the decision for prostate biopsy. Can be used prior to initial biopsy or in patients with prior negative biopsy who remain at elevated risk. Helps clinicians and patients make more informed biopsy decisions.",
    "sensitivity": 90.2,
    "sensitivityNotes": "90.2% sensitivity (95% CI: 86.4%-93.0%) for high-grade prostate cancer in prospective multicenter validation study (n=888).",
    "sensitivityCitations": "FDA PMA clinical data; Klein EA et al. Eur Urol 2017",
    "specificity": 45.5,
    "specificityNotes": "45.5% specificity (95% CI: 41.4%-49.6%) for high-grade prostate cancer. Specificity is 2-3x higher than traditional PSA tests, potentially avoiding up to 46% of unnecessary biopsies.",
    "specificityCitations": "FDA PMA clinical data; Klein EA et al. Eur Urol 2017",
    "ppv": 47.7,
    "ppvNotes": "47.7% PPV (95% CI: 45.7%-49.8%) for high-grade prostate cancer.",
    "ppvCitations": "FDA PMA clinical data",
    "npv": 89.3,
    "npvNotes": "89.3% NPV (95% CI: 85.6%-92.2%) for high-grade prostate cancer, providing high confidence in negative results.",
    "npvCitations": "FDA PMA clinical data",
    "auc": 0.783,
    "aucNotes": "AUC of 0.783 (95% CI: 0.752-0.814) for high-grade prostate cancer, outperforming total PSA and % free PSA.",
    "aucCitations": "FDA PMA clinical data",
    "fdaStatus": "FDA PMA Approved (December 2025)",
    "fdaStatusNotes": "FDA Premarket Approval (PMA) granted December 1, 2025. Previously offered as CLIA LDT since 2020. Breakthrough Device Designation granted October 2019.",
    "fdaStatusCitations": "https://www.businesswire.com/news/home/20251201324198/en/FDA-Approves-IsoPSA----Cleveland-Diagnostics-Novel-Blood-Based-Prostate-Cancer-Test",
    "nccnRecommended": true,
    "nccnGuidelinesAligned": ["Prostate Cancer Early Detection"],
    "nccnGuidelinesNotes": "Included in NCCN Prostate Cancer Early Detection Guidelines (2025) for use prior to biopsy and in patients with prior negative biopsy at higher risk for clinically significant prostate cancer. Also in AUA/SUO Early Detection of Prostate Cancer Guideline (2023).",
    "nccnGuidelinesCitations": "NCCN Guidelines Prostate Cancer Early Detection v1.2026",
    "reimbursement": "Medicare",
    "reimbursementNote": "Medicare coverage established. Commercial payer coverage for 140 million covered lives. More IsoPSAs ordered in first full year as LDT than Guardant360 tests in first 3 years.",
    "reimbursementCitations": "Cleveland Diagnostics; Sameer Rohatgi communication Dec 2025",
    "commercialPayers": ["Multiple commercial payers (140M covered lives)"],
    "tat": "3-5 days",
    "tatNotes": "Results typically available in 3-5 days from sample receipt.",
    "tatCitations": "https://www.isopsa.com/for-patients/",
    "sampleRequirements": "Blood draw in Streck tube",
    "sampleRequirementsNotes": "Simple blood draw collected in Streck tube. No DRE required prior to collection.",
    "sampleRequirementsCitations": "https://www.clevelanddx.com/isopsa-testing",
    "clinicalAvailability": "Commercially available in US (LDT since 2020, FDA PMA December 2025)",
    "clinicalAvailabilityNotes": "Available through Cleveland Diagnostics CLIA lab and Quest Diagnostics. IVD kit format enables deployment on standard clinical analyzers (Roche COBAS, Siemens, Abbott) at any laboratory.",
    "clinicalAvailabilityCitations": "https://www.clevelanddx.com",
    "availableRegions": ["US"],
    "clinicalTrials": "Prospective multicenter validation study (n=888 patients scheduled for prostate biopsy)",
    "clinicalTrialsCitations": "FDA PMA clinical data; Klein EA et al. Eur Urol 2017",
    "totalParticipants": 888,
    "totalParticipantsNotes": "888 patients in prospective multicenter validation study. Additional longitudinal outcome data published in Urology 2025.",
    "numPublications": 10,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Extensive publication portfolio including Klein EA et al. Eur Urol 2017 (initial validation), Stovsky M et al. J Urol 2019, decision analysis in Urol Pract 2022, and longitudinal outcomes in Urology 2025.",
    "numPublicationsCitations": "https://www.clevelanddx.com/news-archive",
    "publicationsExampleCitations": ["Klein EA et al. Eur Urol 2017", "Stovsky M et al. J Urol 2019", "Abdallah et al. Urology 2025"],
    "technologyDifferentiator": "Only FDA-approved protein structure-based cancer diagnostic. IsoClear platform measures structural differences in proteins rather than concentration. Deployable on standard clinical analyzers (Roche COBAS, Siemens, Abbott) enabling broad access from academic centers to community urology practices - not limited to centralized specialty labs.",
    "regulatoryStatusNotes": "FDA PMA approved December 2025. Breakthrough Device Designation 2019. In NCCN and AUA/SUO guidelines. First protein structure-based cancer blood test to receive FDA approval.",
    "vendorDataSource": "Sameer Rohatgi (Cleveland Diagnostics) communication Dec 2025"
  },
  // ============================================
  // IVD KITS - Laboratory Kits for Treatment Decision Support / CGP
  // ============================================
  {
    "id": "tds-kit-1",
    "name": "TruSight Oncology Comprehensive (TSO Comp)",
    "vendor": "Illumina",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 517 genes; detects SNVs, indels, CNAs, fusions/rearrangements; reports TMB, MSI status",
    "genesAnalyzed": 517,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "First FDA-approved distributable CGP IVD kit. Enables hospitals to bring comprehensive genomic profiling in-house. CE-IVD since March 2022.",
    "fdaStatus": "FDA-approved (Aug 2024); CE-IVD",
    "fdaCompanionDxCount": 2,
    "fdaCompanionDxNotes": "FDA approval includes CDx claims for NTRK fusions (pan-tumor) and RET fusions (NSCLC). TMB and MSI reported as biomarkers but not CDx-labeled. Additional CDx claims may expand post-approval.",
    "tmb": "Yes",
    "tmbNotes": "TMB calculated and reported; supports pembrolizumab TMB-H indication",
    "msi": "Yes",
    "msiNotes": "MSI status determined from NGS data",
    "reimbursement": "Medicare LCD (MolDX)",
    "commercialPayers": ["UnitedHealthcare", "Aetna", "Cigna"],
    "clinicalAvailability": "FDA-approved IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "First FDA-approved pan-cancer CGP IVD kit. Enables decentralized in-house CGP testing at hospitals with NextSeq 550Dx. Complete workflow solution with TruSight Oncology Analysis software."
  },
  {
    "id": "tds-kit-2",
    "name": "GeneseeqPrime",
    "vendor": "Geneseeq Technology",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq/NovaSeq",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS panel covering 425 cancer-related genes; detects SNVs, indels, CNAs, fusions; reports TMB and MSI",
    "genesAnalyzed": 425,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA 510(k) cleared August 2025 (K-number pending publication). Also CE-IVDR and NMPA (China) approved. First Chinese CGP to receive FDA clearance.",
    "fdaStatus": "FDA 510(k) cleared (Aug 2025); CE-IVDR; NMPA",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Emerging - new FDA clearance",
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Global regulatory approvals (FDA, CE-IVDR, NMPA). Fresh FDA clearance (Sep 2025). Established in Asia market with US expansion. Competitive pricing expected."
  },
  {
    "id": "tds-kit-3",
    "name": "PGDx elio tissue complete",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering ~500 genes; comprehensive solid tumor profiling including SNVs, indels, CNAs, MSI, TMB",
    "genesAnalyzed": 505,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "FDA-cleared and CE-IVDR (July 2025). First and only test CE-marked for comprehensive solid tumor profiling under new EU IVDR regulation.",
    "fdaStatus": "FDA-cleared; CE-IVDR (Jul 2025)",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Medicare LCD coverage",
    "commercialPayers": ["UnitedHealthcare", "Aetna"],
    "clinicalAvailability": "FDA-cleared IVD kit",
    "tat": "10-14 days",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First CE-IVDR comprehensive CGP kit. Part of elio platform family including plasma focus Dx for liquid biopsy. PGDx analytics platform included."
  },
  {
    "id": "tds-kit-4",
    "name": "Oncomine Comprehensive Assay Plus",
    "vendor": "Thermo Fisher Scientific",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Ion GeneStudio S5",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Amplicon-based NGS covering 500+ genes from DNA and RNA; detects SNVs, indels, CNAs, and fusions including novel fusions via RNA",
    "genesAnalyzed": 500,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "Primarily positioned for oncology research. DNA+RNA workflow captures both mutation and fusion biomarkers. Popular choice for labs with Ion Torrent infrastructure. CE-IVD/IVDR status requires verification.",
    "fdaStatus": "RUO in US; CE-IVD status pending verification",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "CE-IVD kit",
    "tat": "5-7 days",
    "totalParticipants": 20000,
    "numPublications": 80,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ion Torrent amplicon-based sequencing - lower DNA input requirements than hybrid-capture. DNA+RNA workflow in single assay. Strong in APAC market. Automated Genexus workflow option available."
  },
  {
    "id": "tds-kit-5",
    "name": "TSO 500",
    "vendor": "Illumina",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "NextSeq 500/550/550Dx",
    "sampleCategory": "Tissue",
    "approach": "Tissue CGP",
    "method": "Hybrid-capture NGS covering 523 genes from DNA and RNA; comprehensive detection of SNVs, indels, CNAs, fusions, TMB, MSI",
    "genesAnalyzed": 523,
    "cancerTypes": ["Pan-solid tumor"],
    "indicationsNotes": "RUO (Research Use Only) in US. CE-IVD marked in EU - widely deployed in European laboratories. Predecessor to TSO Comprehensive (FDA-approved IVD). For clinical use in US, use TSO Comprehensive.",
    "fdaStatus": "RUO in US; CE-IVD in EU",
    "tmb": "Yes",
    "msi": "Yes",
    "reimbursement": "Coverage varies",
    "clinicalAvailability": "CE-IVD kit; RUO in US",
    "tat": "7-10 days",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Established CE-IVD CGP panel with extensive real-world deployment. DNA+RNA enrichment in single workflow. Foundation for TSO Comprehensive."
  },
  // ============================================
  // RECLASSIFIED CDx KITS - Therapy Selection Companion Diagnostics
  // (Moved from TRM - these are primarily CDx, not response monitoring)
  // ============================================
  {
    "id": "tds-kit-6",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas EGFR Mutation Test v2",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800/6800/8800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of 42 EGFR mutations including exon 19 deletions, L858R, T790M resistance mutation, and exon 20 insertions",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for multiple EGFR TKIs. First liquid biopsy test FDA-approved (June 2016). Detects T790M resistance mutation for osimertinib eligibility.",
    "sensitivity": 85,
    "sensitivityNotes": "~85% concordance with tissue for EGFR mutations in plasma",
    "specificity": 98,
    "lod": "0.1% MAF",
    "lodNotes": "Limit of detection varies by mutation; generally 0.1-1% mutant allele frequency",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Liquid biopsy - plasma cfDNA; also validated for tissue",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "leadTimeVsImaging": null,
    "fdaStatus": "FDA-approved CDx (tissue 2013, plasma 2016)",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 50000,
    "numPublications": 200,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Gold standard EGFR liquid biopsy kit. First FDA-approved liquid biopsy CDx. Distributed IVD kit for labs with cobas system. Rapid TAT (1-2 days) vs. NGS-based tests."
  },
  {
    "id": "tds-kit-7",
    "sampleCategory": "Blood/Plasma",
    "name": "cobas KRAS Mutation Test",
    "vendor": "Roche",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "cobas 4800 System",
    "approach": "Tumor-agnostic",
    "method": "Real-time PCR detection of KRAS mutations in codons 12, 13, and 61",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for cetuximab and panitumumab. KRAS wild-type required for anti-EGFR therapy eligibility.",
    "sensitivity": 95,
    "sensitivityNotes": "High concordance with tissue testing",
    "specificity": 99,
    "lod": "1% MAF",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1-2 days",
    "fdaStatus": "FDA-approved CDx",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 20000,
    "numPublications": 100,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rapid PCR-based KRAS testing for CRC. Distributed IVD kit enables in-house testing. Essential for anti-EGFR therapy decisions."
  },
  {
    "id": "tds-kit-8",
    "sampleCategory": "Blood/Plasma",
    "name": "therascreen EGFR RGQ PCR Kit",
    "vendor": "QIAGEN",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Rotor-Gene Q MDx",
    "approach": "Tumor-agnostic",
    "method": "Scorpions ARMS real-time PCR for EGFR exon 19 deletions, L858R, T790M, and other sensitizing mutations",
    "cancerTypes": ["NSCLC"],
    "targetPopulation": "NSCLC patients for EGFR TKI therapy selection",
    "indicationsNotes": "CE-IVD marked. Widely used in EU and Asia. FDA-approved for tissue; CE-IVD for plasma.",
    "sensitivity": 80,
    "sensitivityNotes": "~80% sensitivity for major EGFR mutations in plasma",
    "specificity": 98,
    "lod": "1% MAF",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "1 day",
    "fdaStatus": "FDA-approved (tissue); CE-IVD (plasma)",
    "reimbursement": "Coverage varies by region",
    "clinicalAvailability": "CE-IVD kit; FDA-approved for tissue",
    "totalParticipants": 30000,
    "numPublications": 150,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Rotor-Gene Q platform common in many molecular labs. Rapid same-day results. Lower capital equipment cost than cobas system."
  },
  {
    "id": "tds-kit-9",
    "sampleCategory": "Blood/Plasma",
    "name": "OncoBEAM RAS CRC Kit",
    "vendor": "Sysmex Inostics",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "OncoBEAM System",
    "approach": "Tumor-agnostic",
    "method": "BEAMing (Beads, Emulsion, Amplification, Magnetics) digital PCR for extended RAS panel including KRAS exons 2-4 and NRAS exons 2-4",
    "cancerTypes": ["Colorectal cancer"],
    "targetPopulation": "mCRC patients for anti-EGFR therapy selection",
    "indicationsNotes": "CE-IVD marked for RAS testing in mCRC. Extended RAS panel covers all clinically relevant mutations. Ultra-sensitive digital PCR platform.",
    "sensitivity": 95,
    "sensitivityNotes": "BEAMing digital PCR provides high sensitivity for low-frequency mutations",
    "specificity": 99,
    "lod": "0.02% MAF",
    "lodNotes": "Digital PCR achieves 0.02% MAF sensitivity - among the most sensitive RAS tests",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "3-5 days",
    "fdaStatus": "CE-IVD",
    "reimbursement": "Coverage varies; reimbursed in EU",
    "clinicalAvailability": "CE-IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "Ultra-sensitive digital PCR (BEAMing) achieves 0.02% MAF - one of the most sensitive RAS liquid biopsy tests. Extended RAS panel for comprehensive therapy selection."
  },
  {
    "id": "tds-kit-10",
    "sampleCategory": "Blood/Plasma",
    "name": "PGDx elio plasma focus Dx",
    "vendor": "Labcorp (Personal Genome Diagnostics)",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "Illumina NextSeq 550Dx",
    "approach": "Tumor-agnostic",
    "method": "NGS-based ~70-gene ctDNA panel; detects SNVs, indels, CNAs, and select fusions across pan-solid tumor biomarkers",
    "cancerTypes": ["Pan-solid tumor"],
    "targetPopulation": "Advanced solid tumor patients for therapy selection",
    "indicationsNotes": "FDA De Novo authorized - first FDA-authorized pan-tumor liquid biopsy IVD kit. Enables decentralized NGS liquid biopsy testing.",
    "sensitivity": 90,
    "sensitivityNotes": "≥90% analytical sensitivity across variant types at LoD; multi-gene panel sensitivity varies by biomarker and VAF",
    "specificity": 95,
    "specificityNotes": "≥95% analytical specificity in validation studies; >99.9% NPV across variant types",
    "lod": "0.5% MAF",
    "lodNotes": "Analytical sensitivity ~0.5% VAF for most variants",
    "requiresTumorTissue": "No",
    "requiresMatchedNormal": "No",
    "tat": "5-7 days",
    "fdaStatus": "FDA De Novo authorized",
    "reimbursement": "Medicare LCD coverage",
    "clinicalAvailability": "FDA-authorized IVD kit",
    "totalParticipants": 5000,
    "numPublications": 30,
    "technologyDifferentiator": "First FDA-authorized pan-tumor liquid biopsy IVD kit. Enables hospitals to bring NGS liquid biopsy in-house. Part of elio platform including tissue CGP (elio tissue complete)."
  },
  {
    "id": "tds-kit-11",
    "sampleCategory": "Bone Marrow/Blood",
    "name": "LeukoStrat CDx FLT3 Mutation Assay",
    "vendor": "Invivoscribe",
    "productType": "Laboratory IVD Kit",
    "platformRequired": "ABI 3500 Genetic Analyzer",
    "approach": "Targeted CDx",
    "method": "PCR-based detection of FLT3-ITD and TKD mutations; FDA-approved companion diagnostic",
    "cancerTypes": [
      "AML"
    ],
    "targetPopulation": "AML patients for FLT3-targeted therapy selection",
    "indicationsNotes": "FDA-approved companion diagnostic for VANFLYTA (quizartinib), RYDAPT (midostaurin), and XOSPATA (gilteritinib). Primary use is therapy selection at diagnosis.",
    "sensitivity": null,
    "sensitivityNotes": "Designed for mutation detection at diagnosis; sensitivity depends on allelic ratio",
    "lod": "5% ITD ratio",
    "lodNotes": "Clinical cutoff for FLT3-ITD positivity",
    "requiresTumorTissue": "No",
    "requiresTumorTissueNotes": "Uses bone marrow or peripheral blood directly",
    "requiresMatchedNormal": "No",
    "tat": "3 days",
    "fdaStatus": "FDA-approved CDx; CE-IVDR",
    "reimbursement": "Medicare covered as CDx",
    "clinicalAvailability": "FDA-approved IVD kit",
    "totalParticipants": 10000,
    "numPublications": 50,
    "numPublicationsPlus": true,
    "technologyDifferentiator": "FDA-approved companion diagnostic for FLT3-targeted AML therapies. Distributed IVD kit enables in-house testing on ABI genetic analyzers. Essential for quizartinib, midostaurin, and gilteritinib eligibility."
  }
];
